Maturation of human immunodeficiency virus, strain LAV, in vitro. NLM AIDSLINE Important note: Information in this article was accurate in 1988. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


Maturation of human immunodeficiency virus, strain LAV, in vitro.

Intervirology. 1987;27(3):148-53. Unique Identifier : AIDSLINE MED/88032147
Katsumoto T; Hattori N; Kurimura T; Department of Virology, Tottori University School of Medicine,; Yonago, Japan.

Abstract: The budding process of human immunodeficiency virus (HIV), strain LAV, starts with the formation of a crescent electron-dense layer directly underneath the cell membrane of infected CCRF-CEM cells. After completion of the formation of the circle of inner dense layer, immature virions with an electron-lucent center are released from the cells. Serial thin sections and stereo observation of thick sections showed that most of the immature virions adjacent to the cell surface had already come off the cell and some still had very thin connections to the cell. However, on rare occasions, virions at an intermediate stage between immature stage and mature virions with bar-shaped electron-dense cores were observed. Virions with dense cores were never observed to be connected to the cell surface. These observations support the idea that the last step of the maturation of HIV occurs outside the cell and that the electron-dense core seems to develop by rearrangement and dispersion of the substance of the inner dense layer of immature virions.
Keywords: Cell Line Human HIV/*GROWTH & DEVELOPMENT/ULTRASTRUCTURE Microscopy, Electron Virion/ULTRASTRUCTURE JOURNAL ARTICLE

KWDcelllinehumanhiv/KWDgrowth&development/ultrastructuremicroscopy,electronvirion/ultrastructurejournalarticle
880228
M8820336

Copyright © 1988 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1988. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1988. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .